Stockscreener 앱 받기
184.85
0.09%
-0.48
전일 마감가:
$185.33
열려 있는:
$185.99
하루 거래량:
891.97K
Relative Volume:
0.47
시가총액:
$286.63B
수익:
$60.48B
순이익/손실:
$10.40B
주가수익비율:
55.52
EPS:
3.3297
순현금흐름:
$8.05B
1주 성능:
-0.99%
1개월 성능:
-0.02%
6개월 성능:
+99.71%
1년 성능:
+161.28%
1일 변동 폭
$184.76
$187.10
1주일 범위
$183.35
$188.72
52주 변동 폭
$68.61
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
184.82 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,091.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.74 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.92 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.31 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership - marketscreener.com
AstraZeneca's Imfinzi Gets US FDA Nod for Bladder Cancer Combo Therapy - Yahoo Finance UK
CelLBxHealth secures AstraZeneca agreement to provide circulating tumour cell analytics services (CLBX) - Yahoo Finance UK
CelLBxHealth rises 33% after signing AstraZeneca deal - Share Talk
CelLBxHealth shares jump 36% after master services agreement with AstraZeneca - Proactive financial news
Astrazeneca's Imfinzi receives green light from US FDA - Sharecast.com
CelLBxHealth PLC Enters Master Services Agreement With AstraZeneca PLC - marketscreener.com
AstraZeneca’s Imfinzi Plus BCG Approved By FDA For High-risk Bladder Cancer - DirectorsTalk Interviews
CellBxHealth enters master services agreement with AstraZeneca - marketscreener.com
AstraZeneca (AZN) withdraws listing for 1.200% Notes due 2026 from NYSE - Stock Titan
AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer - marketscreener.com
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AstraZeneca PLC stock (US6549022043): FDA extends review for key breast cancer drug as London shares - AD HOC NEWS
ASTRAZENECA : Deutsche Bank keeps a Sell rating - marketscreener.com
AZN Stock Quote Price and Forecast - CNN
Why Are AstraZeneca, GSK and Hikma Lifting FTSE 100 Focus? - Kalkine Media
Expert View: Greencore, Autotrader, Watkin Jones, and Astrazeneca - Citywire
AstraZeneca PLC stock (US6549022043): FDA extends camizestrant review as investors weigh oncology mo - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): FDA extends camizestrant review - AD HOC NEWS
FDA delays decision on AstraZeneca breast cancer pill - BioPharma Dive
AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant - Seeking Alpha
FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know - PharmTech.com
AstraZeneca PLC stock (US6549022043): oncology pipeline, Obesity franchise and US market focus in th - AD HOC NEWS
FDA extends review period for AstraZeneca’s camizestrant breast cancer application - Investing.com India
AstraZeneca (AZN) sees FDA delay but EMA backs camizestrant combo - Stock Titan
Why Are AstraZeneca HSBC And Diageo Trending - Kalkine Media
AstraZeneca PLC ADR Dividends – BCBA:AZN.CI - TradingView
US FDA pushes back decision on Astrazeneca's camizestrant - Sharecast.com
US regulator delays decision on AstraZeneca cancer drug - Financial Times
AstraZeneca says FDA extends breast cancer drug review period - London South East
US FDA extends review of AstraZeneca’s experimental breast cancer pill - Reuters
FTSE 100: AstraZeneca (LSE:AZN) Faces Fresh Market Spotlight - Kalkine Media
US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data - AstraZeneca
AstraZeneca Unit Keeps Cancer Therapy IP Despite Stada Jab - Law360
Astrazeneca Pharma India March-quarter PAT 448.8 million rupees - marketscreener.com
AstraZeneca breast cancer drug camizestrant recommended for EU approval - Investing.com
Datroway extends survival in TNBC as AstraZeneca (NYSE: AZN) gains US ok - Stock Titan
AstraZeneca's Buy Rating Reiterated as BofA Notes 'Busy' Pipeline Path; Estimates Revised - marketscreener.com
CHMP backs AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2‑positive solid tumours in EU - Stock Titan
AstraZeneca plc stock (GB0009895292): oncology approvals and home-market context for UK investors - AD HOC NEWS
AstraZeneca (AZN) gets CHMP backing for camizestrant in ESR1-mutated breast cancer - Stock Titan
Oncology Medicine Development Keeps AstraZeneca Within FTSE 350 - Kalkine Media
AstraZeneca (LSE:AZN) Draws Market Focus as Share Momentum Moderates - Kalkine Media
AstraZeneca PLC stock (US6549022043): cancer portfolio and pipeline in focus after latest oncology d - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): cancer pipeline and diabetes deal keep investors watching - AD HOC NEWS
EU panel backs AstraZeneca breast cancer drug camizestrant By Investing.com - Investing.com Nigeria
AstraZeneca's Enhertu Recommended For EU Approval In HER2-positive Solid Tumours - DirectorsTalk Interviews
AstraZeneca reports Enhertu recommended in EU for HER2+ solid tumours - marketscreener.com
AstraZeneca says Datroway approved in US for 1L triple-negative BC - marketscreener.com
Sir Pascal Soriot: Veterinary Scientist, Pharmaceutical Transformer, and Executive Director and CEO of AstraZeneca - BBN Times
AstraZeneca plc stock (GB0009895292): FDA approval for Datroway puts oncology pipeline in the spotli - AD HOC NEWS
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
0.10%
자본화:
|
볼륨(24시간):